Brian Cheng Analyst PerformanceBiotech Analyst at JPMorgan Chase & Co.Brian Cheng is a stock analyst at JPMorgan Chase & Co. in the healthcare sector, covering 28 publicly traded companies. Over the past year, Brian Cheng has issued 35 stock ratings, including buy, hold, and sell recommendations. While full access to Brian Cheng's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Brian Cheng's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings43 Last 1 YearsBuy Recommendations72.09% 31 Buy RatingsCompanies Covered28 Unique Companies Ratings Distribution43RatingsDistribution of strong buy, buy, hold, and sell ratings by Brian Cheng.RatingPercentageCount Strong Buy0.0%0 ratings Buy72.1%30 ratings Hold18.6%8 ratings Sell9.3%4 ratingsOut of 43 total stock ratings issued by Brian Cheng at JPMorgan Chase & Co., the majority (72.1%) have been Buy recommendations, followed by 18.6% Hold and 9.3% Sell.Best & Worst CallsBest Call0000.0%CGONMay 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%AAPGMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ28 companiesBrian Cheng, an analyst at JPMorgan Chase & Co., currently covers 28 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare28 companies100.0%Brian Cheng of JPMorgan Chase & Co. specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY27 companies96.4%HEALTHCARE PROVIDERS & SERVICES1 company3.6% Brian Cheng's Ratings History at JPMorgan Chase & Co. Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsSTTKShattuck Labs7/24/2026Initiated Coverage$7.09$10.00Overweight$0.0000.00% ROIARWRArrowhead Pharmaceuticals7/17/2026Boost Price Target$73.43$95.00Overweight$0.0000.00% ROITNGXTango Therapeutics7/15/2026Initiated Coverage$29.65$46.00Overweight$0.0000.00% ROIODTXOdyssey Therapeutics6/2/2026Initiated Coverage$16.96$26.00Overweight$0.0000.00% ROITARAProtara Therapeutics5/14/2026Lower Price Target$5.23$26.00Overweight$0.0000.00% ROIKYTXKyverna Therapeutics5/13/2026Lower Price Target$10.44$29.00Overweight$0.0000.00% ROICGONCG Oncology5/11/2026Boost Price Target$69.11$96.00Overweight$0.0000.00% ROIGLUEMonte Rosa Therapeutics5/11/2026Boost Price Target$20.30$31.00Overweight$0.0000.00% ROIXNCRXencor5/11/2026Boost Price Target$12.83$14.00Neutral$0.0000.00% ROIARWRArrowhead Pharmaceuticals5/1/2026Initiated Coverage$73.48$88.00Overweight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. CGONCG Oncology4/17/2026Boost Price Target$68.99$91.00Overweight$0.0000.00% ROIALLOAllogene Therapeutics4/16/2026Upgrade$2.17Neutral$0.0000.00% ROIXNCRXencor3/24/2026Reiterated Rating$12.05$13.00Neutral$0.0000.00% ROIPTGXProtagonist Therapeutics3/19/2026Boost Price Target$101.85$106.00Overweight$0.0000.00% ROITARAProtara Therapeutics3/4/2026Initiated Coverage$6.15$27.00Overweight$0.0000.00% ROIEIKNEikon Therapeutics3/2/2026Initiated Coverage$13.78$29.00Overweight$0.0000.00% ROITGTXTG Therapeutics2/2/2026Lower Price Target$29.10$46.00Overweight$0.0000.00% ROIKYMRKymera Therapeutics12/10/2025Boost Price Target$87.77$125.00Overweight$0.0000.00% ROIOPKOPKO Health11/20/2025Initiated Coverage$1.31Neutral$0.0000.00% ROINTLAIntellia Therapeutics11/7/2025Reiterated Rating$12.32$5.00Underweight$0.0000.00% ROIPTGXProtagonist Therapeutics11/7/2025Boost Price Target$79.83$81.00Overweight$0.0000.00% ROIRVMDRevolution Medicines11/6/2025Boost Price Target$61.38$82.00Overweight$0.0000.00% ROIXNCRXencor11/6/2025Lower Price Target$14.00$18.00Overweight$0.0000.00% ROIZYMEZymeworks10/16/2025Boost Price Target$18.62$23.00Overweight$0.0000.00% ROIALLOAllogene Therapeutics10/10/2025Reiterated Rating$1.51Underweight$0.0000.00% ROIPLRXPliant Therapeutics10/10/2025Reiterated Rating$1.54Underweight$0.0000.00% ROIABSIAbsci10/2/2025Initiated Coverage$3.13Overweight$0.0000.00% ROIIMVTImmunovant9/30/2025Lower Price Target$16.06$33.00Overweight$0.0000.00% ROICGONCG Oncology9/26/2025Boost Price Target$36.48$47.00Overweight$0.0000.00% ROICRSPCRISPR Therapeutics9/18/2025Initiated Coverage$59.07$70.00Overweight$0.0000.00% ROIROIVRoivant Sciences9/18/2025Boost Price Target$15.42$20.00Overweight$0.0000.00% ROIPGENPrecigen8/15/2025Upgrade$1.85Neutral$0.0000.00% ROIIMVTImmunovant8/12/2025Lower Price Target$15.26$37.00Overweight$0.0000.00% ROIIMNMImmunome8/7/2025Lower Price Target$9.87$22.00Overweight$0.0000.00% ROIALLOAllogene Therapeutics8/4/2025Reiterated Rating$1.08Neutral$0.0000.00% ROIITOSiTeos Therapeutics5/13/2025Downgrade$8.02$8.00Neutral$0.0000.00% ROICGONCG Oncology5/2/2025Initiated Coverage$27.74$41.00Overweight$00.0000.00% ROIAAPGAscentage Pharma Group International3/27/2025Initiated Coverage$18.37Overweight$00.0000.00% ROIITOSiTeos Therapeutics3/6/2025Lower Price Target$7.11$15.00Overweight$0.0000.00% ROIPTGXProtagonist Therapeutics3/4/2025Boost Price Target$38.50$57.00Overweight$00.0000.00% ROIThe REAL Reason Trump is Invading Iran (Ad)For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.Click here to find out what it is.NTLAIntellia Therapeutics2/28/2025Reiterated Rating$10.86$13.00Neutral$00.0000.00% ROIPTGXProtagonist Therapeutics2/4/2025Boost Price Target$37.66$53.00Overweight$00.0000.00% ROICRGXCARGO Therapeutics1/30/2025Downgrade$13.19Underweight$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupThe Goldman Sachs GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital Markets Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
